Furthermore, when this oncolytic therapy is combined with a HER2-redirected CAR, the decrease in the survival of triple-positive HER2/ EphA2/ A549 tumor cells is accelerated, indicating that this method is effective in addressing the heterogeneity of cold tumors and preventing CAR-mediated antigen evasion [173]. The gene discussed is ERBB2; the disease is neoplasm.